TOP TEN perturbations for Q6W0C5 (Homo sapiens)

Organism: Homo sapiens
Gene: Q6W0C5
Selected probe(set): 231385_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q6W0C5 (231385_at) across 5654 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / Hep-G2

Relative Expression (log2-ratio):3.893314
Number of Samples:8 / 9
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):3.8799186
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

clonidine study 5 (1615 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-2.786149
Number of Samples:3 / 8
Experimental clonidine study 5 (1615 uM; hES-Heps)
hES-Heps cells exposed to 1615 uM clonidine (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:, , , ,
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

methapyrilene study 7 (330 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-2.6837626
Number of Samples:4 / 8
Experimental methapyrilene study 7 (330 uM; hES-Heps)
hES-Heps cells exposed to 330 uM methapyrilene (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

PMA study 8 (0.11 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-2.5189867
Number of Samples:3 / 8
Experimental PMA study 8 (0.11 uM; hES-Heps)
hES-Heps cells exposed to 0.11 uM PMA (dissolved in 0.5% v/v DMSO) for 72 hours. Synonyms: phorbol-12-myristat-13-acetate (PMA), tetradecanoylphorbol-acetate (TPA), tetradecanoyl phorbol acetate, 12-O-tetradecanoylphorbol-13-acetate. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):-2.4047856
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (15d)

Relative Expression (log2-ratio):-1.9103265
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.

cyclophosphamide study 6 (8155 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-1.6598482
Number of Samples:3 / 8
Experimental cyclophosphamide study 6 (8155 uM; hES-Heps)
hES-Heps cells exposed to 8155 uM cyclophosphamide (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):-1.6084309
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-1.3717175
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.